Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.

Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.

Item
http://www.wikidata.org/entity/Q38190100
Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety.Estimating the health care burden of prescription opioid abuse in five European countriesThe economic burden of diagnosed opioid abuse among commercially insured individuals.The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals.Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.Economic Burden of Prescription Opioid Misuse and Abuse: A Systematic Review.Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.Drug Formulation Advances in Extended-Release Medications for Pain Control.Prevalence of Prescription Opioid Misuse/Abuse as Determined by International Classification of Diseases Codes: A Systematic Review.Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.Potential cost-shifting and hidden costs and risks in the economic analysis of opioid abuse-deterrent formulations.Abuse-deterrent opioids: an update on current approaches and considerations.Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects.The Economic Burden of Abuse of Prescription Opioids: A Systematic Literature Review from 2012 to 2017
P2860

Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.

Item
http://www.wikidata.org/entity/Q38190100
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Medical cost savings associate ...... eterrent technology in the US.
@en
type
label
Medical cost savings associate ...... eterrent technology in the US.
@en
prefLabel
Medical cost savings associate ...... eterrent technology in the US.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P356
P1433
P1476
Medical cost savings associate ...... eterrent technology in the US.
@en
P2093
P304
P31
P356
10.3111/13696998.2014.897628
P407
P433
P478
P577
P5875
P698
P921